Table 1.
Summary of included studies and donor characteristics.
| Author | Year | Period | Country | Design | Samples size | Age (years) | Gender | Type of donor | Quality | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EVLP | NEVLP | EVLP | NEVLP | EVLP | NEVLP | EVLP | NEVLP | ||||||
| Koch et al. [20] | 2018 | 2016–2017 | Germany | Cohort | 11 | 41 | 54±14 | 54±16 | F 3, M 8 | F 20, M 21 | DBD 11 | DBD 41 | Jadad 3 |
| Warnecke et al. [16] | 2018 | 2011–2014 | USA, Europe, Australia, and Canada | RCT | 151 | 169 | 42.2±14.4 | 40.2±13.7 | F 72, M 79 | F 67, M 102 | NA | NA | NOS 8 |
| Nilsson et al. [21] | 2018 | 2011–2015 | Sweden | Prospective cohort | 61 | 271 | NA | NA | NA | NA | DBD 61 | DBD 271 | NOS 8 |
| Zhang et al. [22] | 2018 | 2012–2016 | Netherlands | Cohort | 9 | 18 | 41±12.7 | 52±16.3 | F 5, M 4 | F 9, M 9 | DBD6, DCD 3 | DBD 11, DCD 7 | NOS 7 |
| Slama et al. [17] | 2017 | 2013–2015 | Austria | RCT | 35 | 41 | 45 (18–71) | 44 (19–76) | F 18, M 17 | F 12, M 27 | DBD 35 | DBD 41 | Jadad 3 |
| Luc et al. [18] | 2017 | 2011–2015 | Canada | Cohort | 7 | 4 | 48±11 | 40±20 | F 4, M 3 | F 1, M 3 | DCD 7 | DCD 4 | NOS 6 |
| Wallinder et al. [23] | 2016 | 2011–2013 | Sweden | Cohort | 27 | 145 | 47±18 | 50±17 | NA | NA | DBD 27 | DBD 145 | NOS 8 |
| Fisher et al. [24] | 2016 | 2012–2014 | UK (five centers) | Cohort | 18 | 184 | 50.5 (22–61) | 44 (10–68) | F 8, M 10 | F 96, M 86 | DBD 13, DCD 5 | DBD 152, DCD 31 | NOS 7 |
| Machuca et al. [19] | 2015 | 2007–2013 | Canada | Cohort | 28 | 27 | 45±13 | 39±19 | F 13, M 15 | F 11, M 16 | DCD 28 | DCD 27 | NOS 8 |
| Tikkanen et al. [25] | 2015 | 2008–2012 | Canada | Cohort | 63 | 340 | 43.1±14.9 | 45.8±17.6 | F 31, M 32 | F 180, M 160 | DBD 36, DCD 27 | DBD 322, DCD 18 | NOS 8 |
| Fildes et al. [26] | 2015 | 2012–2014 | UK and Sweden | Cohort | 9 | 46 | 54±10.1 | 45±13.1 | F 4, M 5 | F 30, M 16 | NA | NA | NOS 6 |
| Sanchez et al. [15] | 2014 | 2011–2013 | US (six centers) | RCT (abstract) | 42 | 42 | NA | NA | NA | NA | DBD 36, DCD 6 | DBD 41, DCD 1 | NA |
| Sage et al. [29] | 2014 | 2011–2013 | France | Prospective cohort | 31 | 81 | 48 (21–67) | 51 (14–70) | NA | NA | DBD 31 | DBD 81 | NOS 7 |
| Boffini et al. [28] | 2014 | 2011–2013 | Italy | Cohort | 8 | 28 | 44.7±16.2 | 43.3±16.8 | F 7, M 1 | F 13, M 15 | DBD 8 | DBD 28 | NOS 6 |
| Valenza et al. [4] | 2014 | 2011–2013 | Italy | Cohort | 7 | 28 | 54±9 | 40±15 | NA | NA | DBD 7 | DBD 28 | NOS 6 |
| Wallinder et al. [29] | 2014 | 2011–2013 | Sweden | Cohort | 11 | 47 | 56 (19–61) | NA | NA | NA | DBD 11 | DBD 47 | NOS 6 |
| Cypel et al. [30] | 2012 | 2008–2011 | Canada | Cohort | 50 | 253 | Median 45 | Median 45 | NA | NA | DBD 22, DCD 28 | DBD 240, DCD 13 | NOS 8 |
| Zych et al. [31] | 2012 | 2009–2010 | UK | Cohort | 6 | 86 | 43.5±15.1 | NA | F 2, M 4 | NA | DBD 10, DCD 3 | NA | NOS 6 |
| Aigner et al. [32] | 2012 | 2010–2011 | Austria | Prospective cohort | 9 | 119 | 48 (16–58) | NA | NA | NA | DBD 13 | DBD 119 | NOS 6 |
| Lindstedt et al. [33] | 2011 | 2006–2007 | Sweden | Cohort | 6 | 15 | 59 (34–63) | NA | F 3, M 3 | NA | DBD 6 | DBD 15 | NOS 6 |
Data are presented as n/N, mean±SD, median (range). RCT – randomized controlled trial; EVLP – ex vivo lung perfusion; NEVLP – non-EVLP; F – Female; M – Male; DBD – donation after brain death; DCD – donation after cardiac death; NA – not available; SD – standard deviation; NOS – Newcastle-Ottawa Scale.